Trial Profile
The effect of sucroferric oxyhydroxide starting from a small amount
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 13 Feb 2020
Price :
$35
*
At a glance
- Drugs Sucroferric oxyhydroxide (Primary)
- Indications Hyperphosphataemia
- Focus Adverse reactions; Therapeutic Use
- 12 Feb 2020 Status changed from recruiting to discontinued.
- 30 Oct 2019 Planned End Date changed from 31 Dec 2020 to 31 Oct 2020.
- 31 Oct 2018 New trial record